Application of yy1 expression inhibitor in preparation of medicament for breast cancer
An inhibitor and breast cancer technology, applied in the field of gene therapy, can solve problems such as unclear molecular biological mechanisms
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0108] This embodiment relates to the RNA expression of YY1 gene in the tumor tissue of patients with triple negative breast cancer (TNBC):
[0109] First, the expression of the YY1 gene in the Cancer Genome Atlas (TCGA) database was analyzed, and the results were as follows: figure 1 shown; figure 1 Shows the RNA expression situation of YY1 gene in breast cancer tissue and paracancerous tissue in Cancer Genome Atlas Project (TCGA) database; figure 1 It can be seen that the RNA expression level of YY1 gene in 1085 cases of invasive breast cancer tumors (BRCA) is much higher than that of adjacent tissues (291 cases), and YY1 RNA is highly expressed in invasive breast cancer tumors (BRCA).
[0110] In addition, tumor tissues and paracancerous tissues of 4 groups of clinical patients with TNBC were collected for qRT-PCR detection, and the results were as follows: figure 2 as shown ( figure 2 Among them, *p figure 2 Indicates the expression of YY1RNA in tumor tissues and para...
Embodiment 2
[0113] This example involves detecting the effect of KTN1 gene on the proliferation of TNBC cell lines MDA-MB-231 and BT549 cells and the expression of KTN1 RNA.
[0114] KTN1 gene silencing model construction: when the confluence of MDA-MB-231 and BT549 cells reached 70%, the MDA-MB-231 and BT549 cells were divided into three groups, namely siNC' group, siKTN1_1 group and siKTN1_2 group.
[0115] 30 μl lipofectamine2000 liposomes were used to mix 50 nM 15 μL siNC', siKTN1_1 and siKTN1_2, respectively, and then diluted with serum-free and antibiotic-free DMEM medium to obtain three groups of mixed solutions. The total volume of each diluted mixed solution was 400 μl. Wherein, the sequence of siKTN1_1 is: 5'-GAGTGATCTTTCTAGCAAA-3', as shown in SEQ ID NO.1; the sequence of siKTN1_2 is: 5'-GAAGTCTGGTGTAATACAA-3', as shown in SEQ ID NO.2; the siNC' group is a negative control Group, siNC' is provided by Guangzhou Ruibo Biotechnology Co., Ltd., its product name is siR NC#1, and its...
Embodiment 3
[0122] This example involves detecting the effect of knocking down the YY1 gene on the transcription and translation of KTN1.
[0123] First, the correlation between the expression of YY1RNA and the expression of KTN1RNA in invasive breast cancer tumors and adjacent tumors was queried through the TCGA database, Figure 6 Indicates the correlation between YY1RNA expression and KTN1RNA expression in invasive breast cancer tumors and adjacent tumors (correlation coefficient R>0.5, P Figure 6 It can be seen that in invasive breast cancer tumors and adjacent tumors, there is a significant positive correlation between the expression of YY1RNA and the expression of KTN1RNA (correlation coefficient R>0.5, P<0.001), and it is speculated that there is a regulatory function between YY1 gene and KTN1RNA expression.
[0124] Since the expression of genes needs to be regulated by transcription factor proteins, and transcription factors are a kind of specific sequences that can specifically b...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com